These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 12415574)

  • 1. Pharmacokinetics of SB-247083, a potent and selective endothelin(A) receptor antagonist, in the rat, dog, and monkey.
    Ward KW; Azzarano LM; Morgan JA; Gould MJ; Perng CY; Souder PR; Lundberg D; Smith BR
    Biopharm Drug Dispos; 2002 Nov; 23(8):339-49. PubMed ID: 12415574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.
    Murugesan N; Gu Z; Spergel S; Young M; Chen P; Mathur A; Leith L; Hermsmeier M; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Koplowitz B; Humphreys WG; Chong S; Morrison RA; Webb ML; Moreland S; Trippodo N; Barrish JC
    J Med Chem; 2003 Jan; 46(1):125-37. PubMed ID: 12502366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey.
    Ward KW; Azzarano LM
    J Pharmacol Exp Ther; 2004 Aug; 310(2):703-9. PubMed ID: 15056727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelin receptor antagonists.
    Motte S; McEntee K; Naeije R
    Pharmacol Ther; 2006 Jun; 110(3):386-414. PubMed ID: 16219361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase.
    Austin NE; Baldwin SJ; Cutler L; Deeks N; Kelly PJ; Nash M; Shardlow CE; Stemp G; Thewlis K; Ayrton A; Jeffrey P
    Xenobiotica; 2001; 31(8-9):677-86. PubMed ID: 11569533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance.
    Ward KW; Smith BR
    Drug Metab Dispos; 2004 Jun; 32(6):603-11. PubMed ID: 15155551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin receptor antagonists in preclinical models of pulmonary hypertension.
    Pullamsetti SS; Schermuly RT
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():3-13. PubMed ID: 19335741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist.
    Ward KW; Azzarano LM; Bondinell WE; Cousins RD; Huffman WF; Jakas DR; Keenan RM; Ku TW; Lundberg D; Miller WH; Mumaw JA; Newlander KA; Pirhalla JL; Roethke TJ; Salyers KL; Souder PR; Stelman GJ; Smith BR
    Drug Metab Dispos; 1999 Nov; 27(11):1232-41. PubMed ID: 10534306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist.
    Fujitaki JM; Cable EE; Ito BR; Zhang BH; Hou J; Yang C; Bullough DA; Ferrero JL; van Poelje PD; Linemeyer DL; Erion MD
    Drug Metab Dispos; 2008 Nov; 36(11):2393-403. PubMed ID: 18703645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity.
    Dawson LA; Hughes ZA; Starr KR; Storey JD; Bettelini L; Bacchi F; Arban R; Poffe A; Melotto S; Hagan JJ; Price GW
    Neuropharmacology; 2006 Jun; 50(8):975-83. PubMed ID: 16581092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption, distribution, metabolism, and excretion considerations in selection of orally active indole-containing endothelin antagonist.
    Walker DK; Dack KN; Dickinson RP; Fenner KS; James K; Rawson DJ; Smith DA
    Drug Metab Dispos; 2001 Nov; 29(11):1424-31. PubMed ID: 11602517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists.
    Kiesman WF; Zhao J; Conlon PR; Dowling JE; Petter RC; Lutterodt F; Jin X; Smits G; Fure M; Jayaraj A; Kim J; Sullivan G; Linden J
    J Med Chem; 2006 Nov; 49(24):7119-31. PubMed ID: 17125264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization.
    Ward KW; Proksch JW; Azzarano LM; Salyers KL; McSurdy-Freed JE; Molnar TM; Levy MA; Smith BR
    Pharm Res; 2001 Sep; 18(9):1336-44. PubMed ID: 11683250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species.
    Choo EF; Driscoll JP; Feng J; Liederer B; Plise E; Randolph N; Shin Y; Wong S; Ran Y
    Xenobiotica; 2009 Sep; 39(9):700-9. PubMed ID: 19552528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.
    Iglarz M; Binkert C; Morrison K; Fischli W; Gatfield J; Treiber A; Weller T; Bolli MH; Boss C; Buchmann S; Capeleto B; Hess P; Qiu C; Clozel M
    J Pharmacol Exp Ther; 2008 Dec; 327(3):736-45. PubMed ID: 18780830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic properties of TDP4815 after single intravenous and oral administrations to rat, rabbit, monkey, dog and in vitro drug metabolism.
    Chen Y; Cheng D; Tio C; Kagan N; Eisennagel S; Dasgupta M; Tomczuk B; Bone R; Huebert N
    Biopharm Drug Dispos; 2008 Apr; 29(3):127-38. PubMed ID: 18186144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737): identification of an unusual N-acetylglucosamine conjugate in the cynomolgus monkey.
    Johnson BM; Kamath AV; Leet JE; Liu X; Bhide RS; Tejwani RW; Zhang Y; Qian L; Wei DD; Lombardo LJ; Shu YZ
    Drug Metab Dispos; 2008 Dec; 36(12):2475-83. PubMed ID: 18787055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'methyl-4'-(5-methyl-1,2,3-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): a novel, potent and selective 5-HT1B receptor antagonist.
    Scott C; Langmead CJ; Clarke KL; Wyman P; Smith PW; Starr KR; Dawson LA; Price GW; Hagan JJ; Watson J
    Neuropharmacology; 2006 Jun; 50(8):984-90. PubMed ID: 16546225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human.
    Wu Y; Loper A; Landis E; Hettrick L; Novak L; Lynn K; Chen C; Thompson K; Higgins R; Batra U; Shelukar S; Kwei G; Storey D
    Int J Pharm; 2004 Nov; 285(1-2):135-46. PubMed ID: 15488686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.